ATE361067T1 - Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen - Google Patents

Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen

Info

Publication number
ATE361067T1
ATE361067T1 AT02745640T AT02745640T ATE361067T1 AT E361067 T1 ATE361067 T1 AT E361067T1 AT 02745640 T AT02745640 T AT 02745640T AT 02745640 T AT02745640 T AT 02745640T AT E361067 T1 ATE361067 T1 AT E361067T1
Authority
AT
Austria
Prior art keywords
alzheimer
treatment
neurodegenerative diseases
inhibitors
tau aggregation
Prior art date
Application number
AT02745640T
Other languages
English (en)
Inventor
Claude M Wischik
David Horsley
Janet E Rickard
Charles R Harrington
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Application granted granted Critical
Publication of ATE361067T1 publication Critical patent/ATE361067T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02745640T 2001-07-16 2002-07-16 Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen ATE361067T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0117326.9A GB0117326D0 (en) 2001-07-16 2001-07-16 Napthoquinone-type inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
ATE361067T1 true ATE361067T1 (de) 2007-05-15

Family

ID=9918593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745640T ATE361067T1 (de) 2001-07-16 2002-07-16 Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen

Country Status (13)

Country Link
US (1) US7605179B2 (de)
EP (1) EP1408952B1 (de)
JP (1) JP5147157B2 (de)
CN (1) CN1313088C (de)
AT (1) ATE361067T1 (de)
AU (1) AU2002317354B2 (de)
CA (1) CA2451422C (de)
DE (1) DE60219917T2 (de)
ES (1) ES2287292T3 (de)
GB (1) GB0117326D0 (de)
HK (1) HK1063012A1 (de)
SG (1) SG148846A1 (de)
WO (1) WO2003007933A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
AU2004251511A1 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
WO2005053609A2 (en) * 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
WO2006007864A1 (en) * 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
FR2874923B1 (fr) * 2004-09-07 2006-10-27 Trophos Sa Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation
US7790881B2 (en) 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
JP4734602B2 (ja) 2004-12-21 2011-07-27 Ｄｏｗａエレクトロニクス株式会社 保存安定性に優れた窒化鉄系磁性粉末
JP4822312B2 (ja) * 2005-05-13 2011-11-24 学校法人慶應義塾 ナフトキノン誘導体化合物
KR100699945B1 (ko) * 2005-11-24 2007-03-26 (주) 디지탈바이오텍 나프토퀴논계 화합물을 함유하는 인지기능 장애의 예방 및 치료용 조성물
US8263589B2 (en) 2006-03-29 2012-09-11 Wista Laboratories Ltd. Inhibitors of protein aggregation
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
AU2007265631B2 (en) * 2006-06-23 2012-11-08 The Feinstein Institute For Medical Research Inhibitors of A-Beta and synuclein aggregation
JP5537151B2 (ja) 2007-04-05 2014-07-02 株式会社Ｊ−オイルミルズ 精神安定剤および機能性食品
WO2009033151A1 (en) * 2007-09-07 2009-03-12 The Trustees Of Columbia University In The City Of New York Tau protein screening assay
EP2060256A1 (de) * 2007-11-16 2009-05-20 Gnosis S.p.A. Auf Menaquinolen basierende pharmazeutische und nutrazeutische Zusammensetzungen
GB0816269D0 (en) 2008-09-05 2008-10-15 Univ Ramot Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease
WO2011119842A1 (en) 2010-03-25 2011-09-29 The J. David Gladstone Institutes Compositions and methods for treating neurological disorders
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2012019029A2 (en) * 2010-08-06 2012-02-09 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with naphthoquinones
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
EP3345545B1 (de) 2011-04-21 2021-10-20 The Regents of The University of California Funktionalisierte magnetische nanoteilchen und ihre verwendung bei der abbildung von amyloider plaque und neurofibrillären bündeln
WO2012170773A1 (en) * 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
JP6126531B2 (ja) 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
WO2013115867A1 (en) 2012-02-05 2013-08-08 Biodesy, Llc Methods for identifying modulators of ras using nonlinear techniques
MY176838A (en) 2012-08-16 2020-08-24 Ipierian Inc Methods of treating a tauopathy
WO2014039917A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
EP2914291B1 (de) 2012-11-02 2022-02-23 Bioverativ USA Inc. Anti-komplement-c1s-antikörper und verwendungen davon
WO2014162737A1 (ja) 2013-04-02 2014-10-09 学校法人同志社 タウ凝集阻害剤
WO2014200921A1 (en) 2013-06-10 2014-12-18 Ipierian, Inc. Methods of treating a tauopathy
WO2014201435A1 (en) * 2013-06-13 2014-12-18 Biodesy, Inc. Method of screening candidate biochemical entities targeting a target biochemical entity
US20150166476A1 (en) * 2013-12-17 2015-06-18 Yi-Cheng Chen Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
US11911349B2 (en) 2018-03-30 2024-02-27 Nattopharma As Rapidly improving vascular conditions by administering vitamin K
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
CN110025624B (zh) * 2019-05-29 2021-04-02 济宁医学院附属医院 萘醌苷类化合物在老年痴呆中的应用及其药物制备
CN112778092B (zh) * 2020-12-31 2023-03-24 玉溪健坤生物药业有限公司 一种还原型维生素k2的制备方法及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175449A (ja) * 1983-03-26 1984-10-04 Kyushu Kogyo Daigaku シコニンの製造法
JPS61143334A (ja) * 1984-12-18 1986-07-01 Mitsui Petrochem Ind Ltd ５，８−ジヒドロキシ−１，４−ナフトキノン誘導体
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
DE69231222T2 (de) * 1991-02-04 2001-03-01 Ks Biomedix Ltd., Esher Naphtochinonderivate zur Behandlung von chronischen Entzündungen
EP0618968B1 (de) 1991-12-06 1999-10-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Werkzeuge für die Diagnose und Behandlung der Alzheimerschen Krankheit.
EP0778773A1 (de) 1994-08-08 1997-06-18 Albert Einstein College Of Medicine Of Yeshiva University Verfahren zur behandlung und/oder vorbeugung von alzheimer'sche krankheit mit phenothiazine und/oder thioxanthene
JPH08193026A (ja) * 1995-01-12 1996-07-30 Teijin Ltd アミロイドβ蛋白凝集・沈着阻害剤
DE19504003A1 (de) * 1995-02-08 1996-08-14 Martin Dr Kohlmeier Verwendungen eines Vitamins der K-Gruppe
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5804601A (en) 1995-04-10 1998-09-08 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
KR0180791B1 (ko) * 1995-07-24 1999-05-15 김용옥 6-치환-5,8-디옥시-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도
JP3809014B2 (ja) * 1998-05-22 2006-08-16 花王株式会社 養毛・育毛剤
US20020040011A1 (en) * 2000-06-01 2002-04-04 Brown Dennis M. Naphthoquinone compositions and uses thereof
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US6953974B2 (en) 2003-08-26 2005-10-11 Texas Instruments Incorporated EEPROM device and method for providing lower programming voltage
GB0322756D0 (en) 2003-09-29 2003-10-29 Univ Aberdeen Methods of chemical synthesis
SI2322517T1 (sl) 2004-09-23 2019-06-28 Wista Laboratories Ltd. Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC)

Also Published As

Publication number Publication date
US20050107472A1 (en) 2005-05-19
EP1408952A1 (de) 2004-04-21
US7605179B2 (en) 2009-10-20
DE60219917D1 (de) 2007-06-14
CA2451422C (en) 2010-10-19
GB0117326D0 (en) 2001-09-05
CA2451422A1 (en) 2003-01-30
ES2287292T3 (es) 2007-12-16
WO2003007933A1 (en) 2003-01-30
DE60219917T2 (de) 2008-01-17
CN1313088C (zh) 2007-05-02
SG148846A1 (en) 2009-01-29
JP5147157B2 (ja) 2013-02-20
HK1063012A1 (en) 2004-12-10
JP2004534854A (ja) 2004-11-18
AU2002317354B2 (en) 2007-07-19
CN1553800A (zh) 2004-12-08
EP1408952B1 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
DE122012000007I1 (de) Zusammenzetzungen und verfahren zur stabilisierungvon transthyretin und zur hemmung von transthyret infehlfaltung.
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
ATE480235T1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
NO20015247L (no) Glysinspaltingssysteminhibitorer som potensielle antipsykotika
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
ATE553114T1 (de) Verbindungen zur verminderung der aggregation von amyloid-beta-peptid
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
BR0314541A (pt) Tratamento de demência e doença de parkinson
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
DE602004014115D1 (de) Neue amidderivate von 2,2,3,3-tetramethylcyclopropancarbonsäure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1408952

Country of ref document: EP